Results 71 to 80 of about 2,545 (184)
Therapeutic Options in Patients With Lymphoma and Severe Liver Dysfunction
, 2004 To determine the long-term outcome of patients presenting with synchronous lymphoma and severe liver dysfunction and to describe the outcome of patients treated with initial mechlorethamine-based therapy used as a bridge to more conventional chemotherapy.
White, William L +12 more
core +1 more source
Influence of granulocytopenia on canine cerebral ischemia induced by air embolism.
, 1989 We subjected nine dogs with severe granulocytopenia 4 days after the administration of mechlorethamine to 1 hour of cerebral ischemia induced by the controlled, incremental injection of air into the internal carotid artery.
A J Dutka, J M Hallenbeck, P M Kochanek
core +1 more source
Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease.
, 1989 The association between dose intensity of chemotherapy with the rate of complete remission (CR), the duration of disease-free survival (DFS), and overall survival (OS) was separately analyzed for 67 patients initially treated with mechlorethamine ...
A J de Meijer +4 more
core +1 more source
Ebselen oxide attenuates mechlorethamine dermatotoxicity in the mouse ear vesicant model
, 2018 Mechlorethamine (HN2) is an alkylating agent and sulfur mustard mimetic. Topical exposure to HN2 is associated with tissue blistering. Previous work in our laboratory has shown that ebselen (EB-1) possesses anti-vesicant, anti-inflammatory, anti ...
Maria A. Pino (5794640) +5 more
core +1 more source
Reduced intensity treatment in early-stage Hodgkin’s lymphoma
Blood and Lymphatic Cancer: Targets and Therapy, 2011 Prathima Prodduturi, James O ArmitageUniversity of Nebraska Medical Center, Omaha, NE, USAAbstract: Early-stage Hodgkin’s lymphoma which includes patients with Ann Arbor stages I or II, accounts for more than 50% of all cases of the illness and
Armitage JO, Prodduturi P
doaj
, 2016 A series of benzene-substituted analogues of the novel hypoxia-selective cytotoxin N,N-bis(2-chloroethyl)-N-methyl-N-(2-nitrobenzyl)ammonium chloride (3a), together with three corresponding tetrahydroisoquinolinium “cyclic” analogues 21a−23a and two ...
William R. Wilson (210146) +3 more
core +1 more source
, 2012 The reaction of K2PtCl4 with anticancer-alkylating agent mechlorethamine hydrochloride (CH3NH(C2H4Cl)2 x HCl = HN2×HCl), in the molar ratio 1 : 2, affords the complex [H2N2] 2[PtCl4].
Čomić, Ljiljana +5 more
core +1 more source
, 1997 Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy van den Berg, H.; Stuve, W ...
H Van Den Berg
core
, 1984 Thirty-nine patients with advanced Hodgkin's disease were treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Thirty-one of these patients had previously failed to respond to MOPP (mechlorethamine, vincristine, prednisone, and ...
TODESCHINI, Giuseppe +5 more
core
, 2021 Mechlorethamine (HN2) is a type of nitrogen mustard alkylating agent that has been widely applied as an anticancer drug. HN2 is an analog of the corrosive reagent sulfur mustard, which is highly reactive with skin and organisms exposed to HN2 develop ...
Mao, Ganming
core